Merger and acquisition (M&A) activity in the pharmaceutical contract manufacturing industry declined in 2023 compared to 2021-22. High inflation and interest rates along with an uncertain business environment disincentivized investment. Despite fewer deals, the focus shifted towards scaling operations rather than acquiring specialized capabilities, according to GlobalData, a leading data and analytics company. Adam Bradbury, Pharma Analyst at GlobalData, comments: “In 2023, the largest proportion of acquired contract manufacturing and development organizations (CDMOs) had standard capabilities, whereas in prior years, specialized and biologic acquisitions were higher.”
Read the full article: Pharma CMO M&A Activity Shifted Focus to Scaling in 2023, Reveals GlobalData //
Source: https://www.globaldata.com/media/pharma/pharma-cmo-ma-activity-shifts-focus-to-scaling-in-2023-reveals-globaldata/